FDA mulling label change
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Arecommendation by a slim majority of US Food and Drug Administration (FDA) advisory panel members to add label warnings for OTC naproxen’s interaction with aspirin might not lead to packaging changes, after many committee members admitted that they were not impressed with a trial that prompted the FDA to request their help.